Thyrocare Technologies shares rise after promoter Docon sells 10% stake for ₹668 crore

At around 1:02 pm, the stock was trading 2.23% higher at ₹1,272.70 per equity share.

Docon sold 53,32,860 equity shares of Thyrocare at an average price of about ₹1,252.03 apiece through market trades today, i.e., October 24, the latter said in a regulatory filing.

“The number of shares sold constitutes approximately 10% of the total paid-up capital of the company,” it added.

While Docon continues to be a promoter following the transaction, its promoter shareholding stands reduced to 60.93%, compared to the pre-transaction shareholding of 70.98%.

Thyrocare Technologies' stock performance

The scrip has gained more than 2% over the past five days and nearly 5.5% over the month. It surged over 50% in the last six months. On a year-to-date basis, it rose about 38%.

While the stock reached a 52-week high of ₹1,474 on October 15, 2025, it touched a year’s low of ₹658 per equity share on March 4, 2025.

Thyrocare Technologies has a total market capitalisation of ₹6,740.36 crore, as of October 24, 2025, according to data on the NSE.

Q2 results

The company reported an 80% year-on-year (YoY) increase in its net profit to ₹48 crore in the September quarter of FY26, compared to ₹26.7 crore in the corresponding quarter of the previous fiscal year.

Its revenue from operations witnessed a strong 22% YoY growth to ₹216.53 crore during the quarter under review, as against ₹163 crore in the second quarter of FY25, driven by continued momentum in the Pathology segment, which grew 24% YoY.

In addition, the company also announced a ₹7 per share interim dividend on the face value of ₹10 per share with a record date of October 24, 2025. Furthermore, the board of directors also approved the issuance of bonus shares in the ratio of 2:1, for which the record date will be announced later.